Valeant Pharmaceuticals International (VRX) 167.00 $VRX
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - Sat Feb 14, 7:02AM CST
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
Today's Market: Earnings Moving These Stocks, M&A In Pharma And Big Management Shakeups
Matthew Smith - at Seeking Alpha - Fri Feb 13, 8:56AM CST
VRX: 167.00 (-0.50), CAG: 34.83 (-1.59), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), KRFT: 64.42 (-1.75), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96)
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Wall Street Breakfast: GDP Figures Lead Europe Higher
Wall Street Breakfast - at Seeking Alpha - Fri Feb 13, 5:31AM CST
VRX: 167.00 (-0.50), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), GM: 37.62 (-0.40), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), GRPN: 7.97 (+0.51), FSL: 37.53 (+2.83), MT: 11.20 (+0.74)
Shire now on the hunt for Salix
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 12:58AM CST
VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17)
Valeant close to a bid for Salix
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 2:53PM CST
VRX: 167.00 (-0.50), SLXP: 152.35 (+3.17)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
Valeant Pharmaceuticals International Up 11.4% Since SmarTrend Uptrend Call (VRX)
Comtex SmarTrend(R) - Wed Feb 11, 10:04AM CST
SmarTrend identified an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on December 22nd, 2014 at $147.02. In approximately 2 months, Valeant Pharmaceuticals International has returned 11.43% as of today's recent price of $163.82.
VRX: 167.00 (-0.50)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST
TSLA: 203.77 (+0.89), VRX: 167.00 (-0.50), AMX: 21.97 (+0.27), HAL: 44.19 (+1.42), PBR: 6.98 (+0.44), ANTM: 141.05 (-0.95), FSLR: 48.84 (-0.58), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), ARMH: 49.92 (-0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86)
Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST
VRX: 167.00 (-0.50)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon
CNW Group - Tue Feb 10, 4:15PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that no additional qualified bids have been received by the bid deadline provided by the Court-approved bidding procedures for the sale of substantially all of Dendreon's assets. A hearing at which Dendreon and Valeant will seek the required Court approval of the sale is scheduled for February 20, 2015. Valeant expects to close the transaction by the end of February 2015.
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
After Yesterday's Rally of 2.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Feb 10, 4:13PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $161.12 to a high of $164.30. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $163.76 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 167.00 (-0.50)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
Actavis Leads IBD 50 Stocks With Earnings This Week
at Investor's Business Daily - Sat Feb 14, 7:02AM CST
Earnings season is still chugging along past Presidents Day, with several major drugmakers and technology companies yet to disclose eagerly anticipated results. Today's IBD 50 roundup takes a peek at two hot biotechs and one laser-focused tech firm...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), PCYC: 163.28 (+0.23), AKRX: 47.28 (-0.25), JAZZ: 169.69 (+6.89), IPGP: 87.26 (+0.07)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Ackman vs. Icahn: How Two Billionaires, Former Adversaries, Stack Up
at The Street - Fri Feb 13, 10:14AM CST
More than two years have passed since Icahn and Ackman's epic CNBC blowout. Though they've since called a truce, it's worth looking at how these two billionaires stack up today.
AGN: 229.49 (+1.87), HLF: 32.78 (-0.84), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EBAY: 56.47 (+1.73), GCI: 34.77 (-0.07), IEP: 100.21 (+0.28), MTW: 21.86 (+0.34), AAPL: 127.08 (+0.62)
Today's Market: Earnings Moving These Stocks, M&A In Pharma And Big Management Shakeups
Matthew Smith - at Seeking Alpha - Fri Feb 13, 8:56AM CST
VRX: 167.00 (-0.50), CAG: 34.83 (-1.59), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), KRFT: 64.42 (-1.75), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96)
Technical Notes Covering Pharma Equities -- Valeant Pharma Intl., Salix Pharma, Medicines, Hospira, and Horizon Pharma
PR Newswire - Fri Feb 13, 7:45AM CST
Editor Note: For more information about this release, please scroll to bottom.
VRX: 167.00 (-0.50), MDCO: 29.79 (+0.91), HZNP: 16.84 (-0.41), SLXP: 152.35 (+3.17), HSP: 87.35 (unch), VRX.TO: 207.95 (-1.47)
Wall Street Breakfast: GDP Figures Lead Europe Higher
Wall Street Breakfast - at Seeking Alpha - Fri Feb 13, 5:31AM CST
VRX: 167.00 (-0.50), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), GM: 37.62 (-0.40), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), GRPN: 7.97 (+0.51), FSL: 37.53 (+2.83), MT: 11.20 (+0.74)
Shire now on the hunt for Salix
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 12:58AM CST
VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17)
Valeant close to a bid for Salix
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 2:53PM CST
VRX: 167.00 (-0.50), SLXP: 152.35 (+3.17)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Don't Discount Bill Ackman
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 11:13AM CST
Originally Published on January 28, 2015 Bill Ackman wears an almost punchably smug expression. He looks as if he thinks that he is the smartest guy in any room. All the more grating is the fact that, in most rooms, he is right. He has reasons to...
ZTS: 45.46 (-0.33), AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), HHC: 144.41 (+6.41), TPRE: 13.91 (+0.03), PAH: 22.68 (+0.14), CP: 186.30 (-0.54), APD: 152.81 (+0.59), GLRE: 31.99 (+0.01)
Valeant Pharmaceuticals International Up 11.4% Since SmarTrend Uptrend Call (VRX)
Comtex SmarTrend(R) - Wed Feb 11, 10:04AM CST
SmarTrend identified an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on December 22nd, 2014 at $147.02. In approximately 2 months, Valeant Pharmaceuticals International has returned 11.43% as of today's recent price of $163.82.
VRX: 167.00 (-0.50)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Wall Street Breakfast: Apple's Market Cap Closes Above $700B
Wall Street Breakfast - at Seeking Alpha - Wed Feb 11, 5:30AM CST
TSLA: 203.77 (+0.89), VRX: 167.00 (-0.50), AMX: 21.97 (+0.27), HAL: 44.19 (+1.42), PBR: 6.98 (+0.44), ANTM: 141.05 (-0.95), FSLR: 48.84 (-0.58), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), ARMH: 49.92 (-0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86)
Reuters: Valeant close to Dendreon purchase
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 1:49AM CST
VRX: 167.00 (-0.50)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Dendreon Announces Expiration of Bid Deadline in Connection with Agreement to Sell Substantially All Assets to Valeant
Business Wire - Tue Feb 10, 4:15PM CST
--Dendreon and Valeant to Seek Court Approval of Sale on February 20, 2015
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon
CNW Group - Tue Feb 10, 4:15PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that no additional qualified bids have been received by the bid deadline provided by the Court-approved bidding procedures for the sale of substantially all of Dendreon's assets. A hearing at which Dendreon and Valeant will seek the required Court approval of the sale is scheduled for February 20, 2015. Valeant expects to close the transaction by the end of February 2015.
VRX: 167.00 (-0.50), VRX.TO: 207.95 (-1.47)
After Yesterday's Rally of 2.52% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Feb 10, 4:13PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $161.12 to a high of $164.30. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $163.76 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 167.00 (-0.50)
Healthcare stock screen of the month: Accelerating after-tax margins
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 11:21AM CST
MNK: 115.01 (+2.51), BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), BCR: 175.38 (+0.50), EVHC: 36.20 (-0.09), TMO: 127.61 (+0.78), CAH: 86.08 (+0.04), UTHR: 151.11 (+3.59), ILMN: 198.54 (+1.81), ACOR: 36.14 (-0.51), LCI: 57.78 (-0.91), JAZZ: 169.69 (+6.89), SHPG: 239.82 (+6.11), CPHD: 59.62 (+0.72), SYK: 94.51 (+1.14)
